B7-1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy.

ABSTRACT: The incidence of progressive kidney disease associated with diabetes continues to rise worldwide. Current standard therapy with angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers achieves only partial renoprotection, increasing the need for novel therapeutic approaches. Previous studies described B7-1 induction in podocytes of patients with proteinuria, including those with FSGS and type 2 diabetic nephropathy (DN). These findings sparked great excitement in the renal community, implying that abatacept, a costimulatory inhibitor that targets B7-1, could be a novel therapy for diabetic renal disease. Given previous concerns over the value of B7-1 immunostaining and the efficacy of abatacept in patients with recurrent FSGS after renal transplantation, we investigat

SUBMITTER: Gagliardini E 

PROVIDER: S-EPMC4814190 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature